NCT03421288View on ClinicalTrials.gov

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

677

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Gastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Atezolizumab

Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)

DRUG

5-Fluorouracil

Day 1 q2w: 2600 mg/m² IV over 24 hours

DRUG

Calciumfolinat

Day 1 q2w: 200 mg/m² IV over 1 hour

DRUG

Oxaliplatin

Day 1 q2w: 85 mg/m² IV over 2 hours

DRUG

Docetaxel

Day 1 q2w: 50 mg/m² IV over 1 hour

Trial Locations (2)

3008

SAKK Coordinating Center, Bern

60488

Krankenhaus Nordwest, Frankfurt

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

NCT03421288 - Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness | Biotech Hunter | Biotech Hunter